Last updated on October 2018

Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma

Brief description of study

This study seeks to evaluate the tolerability, pharmacokinetics (PK), efficacy, and safety of ABT-414 in Japanese participants with newly diagnosed and recurrent, World Health Organization (WHO) grade III or IV malignant glioma.

Clinical Study Identifier: NCT02590263

Contact Investigators or Research Sites near you

Start Over

AbbVie GK Clinical Trial Registration ...

Dokkyo Medical University Hosp /ID# 150990
Shimotsuga, Japan
  Connect »